SARS-CoV-2-IN-13

SARS-CoV-2-IN-13

• CAS Number: 56961-10-5
• UNSPSC Description: SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1].
• Target Antigen: SARS-CoV
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-anti-virus
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/sars-cov-2-in-13.html
• Solubility: DMSO : ≥ 125 mg/mL
• Smiles: O=C(C1=C(C=CC(Cl)=C1)O)NC2=CC(Cl)=C(C=C2)[N+]([O-])=O
• Molecular Weight: 327.12
• References & Citations: [1]Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported